Home > Alasdair Coles, MSVirtual2020 – Potential of Retinoid-X Receptor Agonists to Promote Remyelination in MS
Multiple Sclerosis

Alasdair Coles, MSVirtual2020 – Potential of Retinoid-X Receptor Agonists to Promote Remyelination in MS

Published Online: October 16th 2020

Alisdair Coles (University of Cambridge, Cambridge, UK) shares exciting phase II findings that highlight the potential of retinoid-X receptor agonists to promote remyelination in relapsing-remitting multiple sclerosis. The interview focuses on his late-breaking presentation entitled: LB01.02 – Phase 2 clinical trial evidence that a retinoid-X receptor agonist promotes remyelination in people with relapsing-remitting multiple sclerosis. Study identifiers: EudraCT number 2014-003145-99; ISRCTN14265371.

Questions

  1. Why has it taken so long to develop remyelination strategies in multiple sclerosis, and what are the potential advantages of this approach compared with existing disease-modifying therapies? (0:06)
  2. Could you give us an overview of the retinoid-X receptor agonist and its mechanism of promoting remyelination? (0:41)
  3. Could you tell us a little about the phase II study you are presenting and its findings? (1:13)
  4. At what stage in the disease course will remyelination strategies cease to be effective? (2:00)
  5. What will be the next step in the clinical development of this agent? (2:26)

Disclosures: Alasdair Coles reports receiving honoraria from Sanofi prior to 2017.

Support: Interview and filming supported by Touch Medical Media.

Filmed as a highlight of the Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020. 

Share this Video
Related Videos In Multiple Sclerosis
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots padlock person play_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar